Compassionate Use of Stannsoporfin as an Adjuvant to Phototherapy to Reduce the Need for Exchange Transfusions
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 15 Dec 2016
At a glance
- Drugs Stannsoporfin (Primary)
- Indications Hyperbilirubinaemia; Neonatal jaundice
- Focus Expanded access; Therapeutic Use
- Sponsors InfaCare Pharmaceutical Corporation
- 12 Dec 2016 Status changed from recruiting to completed.
- 28 May 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 18 Dec 2013 New trial record